Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-7503 SAD and MAD in Healthy Participants
NCT06391827Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DA-7503 in Alzheimer's disease (AD) (4 arms), sponsored by Dong-A ST. Primary endpoints: Pharmacokinetics of DA-7503 single dose oral administration at 5 days and Pharmacokinetics of DA-7503 multiple dose oral administration at 11 days. Started May 2024; status: completed.
02
Drugs
DA-7503
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06391827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391827.